The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics

Alexandra Lucas, Liying Liu, Erbin Dai, Ilze Bot, Kasinath Viswanathan, Ganesh Munuswamy-Ramunujam, Jennifer A. Davids, Mee Y. Bartee, Jakob Richardson, Alexander Christov, Hao Wang, Colin Macaulay, Mark Poznansky, Robert Zhong, Leslie Miller, Erik Biessen, Mary Richardson, Collin Sullivan, Richard Moyer, Mark HattonDavid A. Lomas, Douglas McFadden

Research output: Chapter in Book/Report/Conference proceedingChapter

29 Citations (Scopus)

Abstract

Serine proteinase inhibitors, also called serpins, are an ancient group ing of proteins found in primitive organisms from bacteria, protozoa and horseshoe crabs and thus likely present at the time of the dinosaurs. up to all mammals living today. The innate or inflammatory immune system is also an ancient metazoan regulatory system. providing the first line ofdefense against infection or injury. The innate inflammatory defense response evolved long before acquired. antibody dependent immunity. Viruses have developed highlyeffective stratagems that undermine and block a wide variety ofhost inflammatory and immune responses. Some of the most potent of these immune modifying strategies utilize serpins that have also been developed over millions ofyears. including the hijacking by some viruses for defense against host immune attacks . Serpins represent up to 2-10 percent ofcirculating plasma proteins. regulating actions as wide ranging as thrombosis. inflammation. blood pressure control and even hormone transport. Targeting serpin-regulated immune or inflammatory pathways makes evolutionary sense for viral defense and many of these virus-derived inh ibitory proteins have proven to be highly effective.working at very low concentrations-even down to the femptomolar to picomolar range. We are studying these viral anti-inflammatory proteins as a new class ofimmunomodulatory therapeutic agents derived from their native viral source. One such viral serpin, Serp-I is now in clinical trial (conducted by VIRON Therapeutics, Inc.) for acute unstable coronary syndromes (unstable angina and small heart attacks), representing a 'first in class' therapeutic study. Several other viral serpins are also currently under investigation as anti-inflammatory or anti-immune therapeutics. This chapter describes these original studies and the ongoing analysis ofviral serpins as a new class ofvirus-derived immunotherapeutic.

Original languageEnglish (US)
Title of host publicationPathogen-Derived Immunomodulatory Molecules
EditorsPadraic Fallon
Pages132-156
Number of pages25
DOIs
StatePublished - Dec 1 2009
Externally publishedYes

Publication series

NameAdvances in Experimental Medicine and Biology
Volume666
ISSN (Print)0065-2598

Fingerprint

Serpins
Viruses
Anti-Inflammatory Agents
Proteins
Dinosaurs
Protozoa
Horseshoe Crabs
Serine Proteinase Inhibitors
Mammals
Pressure control
Immune system
Unstable Angina
Blood pressure
Therapeutics
Acute Coronary Syndrome
Blood Proteins
Immune System
Immunity
Bacteria
Thrombosis

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Lucas, A., Liu, L., Dai, E., Bot, I., Viswanathan, K., Munuswamy-Ramunujam, G., ... McFadden, D. (2009). The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics. In P. Fallon (Ed.), Pathogen-Derived Immunomodulatory Molecules (pp. 132-156). (Advances in Experimental Medicine and Biology; Vol. 666). https://doi.org/10.1007/978-1-4419-1601-3_11

The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics. / Lucas, Alexandra; Liu, Liying; Dai, Erbin; Bot, Ilze; Viswanathan, Kasinath; Munuswamy-Ramunujam, Ganesh; Davids, Jennifer A.; Bartee, Mee Y.; Richardson, Jakob; Christov, Alexander; Wang, Hao; Macaulay, Colin; Poznansky, Mark; Zhong, Robert; Miller, Leslie; Biessen, Erik; Richardson, Mary; Sullivan, Collin; Moyer, Richard; Hatton, Mark; Lomas, David A.; McFadden, Douglas.

Pathogen-Derived Immunomodulatory Molecules. ed. / Padraic Fallon. 2009. p. 132-156 (Advances in Experimental Medicine and Biology; Vol. 666).

Research output: Chapter in Book/Report/Conference proceedingChapter

Lucas, A, Liu, L, Dai, E, Bot, I, Viswanathan, K, Munuswamy-Ramunujam, G, Davids, JA, Bartee, MY, Richardson, J, Christov, A, Wang, H, Macaulay, C, Poznansky, M, Zhong, R, Miller, L, Biessen, E, Richardson, M, Sullivan, C, Moyer, R, Hatton, M, Lomas, DA & McFadden, D 2009, The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics. in P Fallon (ed.), Pathogen-Derived Immunomodulatory Molecules. Advances in Experimental Medicine and Biology, vol. 666, pp. 132-156. https://doi.org/10.1007/978-1-4419-1601-3_11
Lucas A, Liu L, Dai E, Bot I, Viswanathan K, Munuswamy-Ramunujam G et al. The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics. In Fallon P, editor, Pathogen-Derived Immunomodulatory Molecules. 2009. p. 132-156. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4419-1601-3_11
Lucas, Alexandra ; Liu, Liying ; Dai, Erbin ; Bot, Ilze ; Viswanathan, Kasinath ; Munuswamy-Ramunujam, Ganesh ; Davids, Jennifer A. ; Bartee, Mee Y. ; Richardson, Jakob ; Christov, Alexander ; Wang, Hao ; Macaulay, Colin ; Poznansky, Mark ; Zhong, Robert ; Miller, Leslie ; Biessen, Erik ; Richardson, Mary ; Sullivan, Collin ; Moyer, Richard ; Hatton, Mark ; Lomas, David A. ; McFadden, Douglas. / The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics. Pathogen-Derived Immunomodulatory Molecules. editor / Padraic Fallon. 2009. pp. 132-156 (Advances in Experimental Medicine and Biology).
@inbook{379a38a4927d45b29207147ca45adbca,
title = "The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics",
abstract = "Serine proteinase inhibitors, also called serpins, are an ancient group ing of proteins found in primitive organisms from bacteria, protozoa and horseshoe crabs and thus likely present at the time of the dinosaurs. up to all mammals living today. The innate or inflammatory immune system is also an ancient metazoan regulatory system. providing the first line ofdefense against infection or injury. The innate inflammatory defense response evolved long before acquired. antibody dependent immunity. Viruses have developed highlyeffective stratagems that undermine and block a wide variety ofhost inflammatory and immune responses. Some of the most potent of these immune modifying strategies utilize serpins that have also been developed over millions ofyears. including the hijacking by some viruses for defense against host immune attacks . Serpins represent up to 2-10 percent ofcirculating plasma proteins. regulating actions as wide ranging as thrombosis. inflammation. blood pressure control and even hormone transport. Targeting serpin-regulated immune or inflammatory pathways makes evolutionary sense for viral defense and many of these virus-derived inh ibitory proteins have proven to be highly effective.working at very low concentrations-even down to the femptomolar to picomolar range. We are studying these viral anti-inflammatory proteins as a new class ofimmunomodulatory therapeutic agents derived from their native viral source. One such viral serpin, Serp-I is now in clinical trial (conducted by VIRON Therapeutics, Inc.) for acute unstable coronary syndromes (unstable angina and small heart attacks), representing a 'first in class' therapeutic study. Several other viral serpins are also currently under investigation as anti-inflammatory or anti-immune therapeutics. This chapter describes these original studies and the ongoing analysis ofviral serpins as a new class ofvirus-derived immunotherapeutic.",
author = "Alexandra Lucas and Liying Liu and Erbin Dai and Ilze Bot and Kasinath Viswanathan and Ganesh Munuswamy-Ramunujam and Davids, {Jennifer A.} and Bartee, {Mee Y.} and Jakob Richardson and Alexander Christov and Hao Wang and Colin Macaulay and Mark Poznansky and Robert Zhong and Leslie Miller and Erik Biessen and Mary Richardson and Collin Sullivan and Richard Moyer and Mark Hatton and Lomas, {David A.} and Douglas McFadden",
year = "2009",
month = "12",
day = "1",
doi = "10.1007/978-1-4419-1601-3_11",
language = "English (US)",
isbn = "9781441916006",
series = "Advances in Experimental Medicine and Biology",
pages = "132--156",
editor = "Padraic Fallon",
booktitle = "Pathogen-Derived Immunomodulatory Molecules",

}

TY - CHAP

T1 - The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics

AU - Lucas, Alexandra

AU - Liu, Liying

AU - Dai, Erbin

AU - Bot, Ilze

AU - Viswanathan, Kasinath

AU - Munuswamy-Ramunujam, Ganesh

AU - Davids, Jennifer A.

AU - Bartee, Mee Y.

AU - Richardson, Jakob

AU - Christov, Alexander

AU - Wang, Hao

AU - Macaulay, Colin

AU - Poznansky, Mark

AU - Zhong, Robert

AU - Miller, Leslie

AU - Biessen, Erik

AU - Richardson, Mary

AU - Sullivan, Collin

AU - Moyer, Richard

AU - Hatton, Mark

AU - Lomas, David A.

AU - McFadden, Douglas

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Serine proteinase inhibitors, also called serpins, are an ancient group ing of proteins found in primitive organisms from bacteria, protozoa and horseshoe crabs and thus likely present at the time of the dinosaurs. up to all mammals living today. The innate or inflammatory immune system is also an ancient metazoan regulatory system. providing the first line ofdefense against infection or injury. The innate inflammatory defense response evolved long before acquired. antibody dependent immunity. Viruses have developed highlyeffective stratagems that undermine and block a wide variety ofhost inflammatory and immune responses. Some of the most potent of these immune modifying strategies utilize serpins that have also been developed over millions ofyears. including the hijacking by some viruses for defense against host immune attacks . Serpins represent up to 2-10 percent ofcirculating plasma proteins. regulating actions as wide ranging as thrombosis. inflammation. blood pressure control and even hormone transport. Targeting serpin-regulated immune or inflammatory pathways makes evolutionary sense for viral defense and many of these virus-derived inh ibitory proteins have proven to be highly effective.working at very low concentrations-even down to the femptomolar to picomolar range. We are studying these viral anti-inflammatory proteins as a new class ofimmunomodulatory therapeutic agents derived from their native viral source. One such viral serpin, Serp-I is now in clinical trial (conducted by VIRON Therapeutics, Inc.) for acute unstable coronary syndromes (unstable angina and small heart attacks), representing a 'first in class' therapeutic study. Several other viral serpins are also currently under investigation as anti-inflammatory or anti-immune therapeutics. This chapter describes these original studies and the ongoing analysis ofviral serpins as a new class ofvirus-derived immunotherapeutic.

AB - Serine proteinase inhibitors, also called serpins, are an ancient group ing of proteins found in primitive organisms from bacteria, protozoa and horseshoe crabs and thus likely present at the time of the dinosaurs. up to all mammals living today. The innate or inflammatory immune system is also an ancient metazoan regulatory system. providing the first line ofdefense against infection or injury. The innate inflammatory defense response evolved long before acquired. antibody dependent immunity. Viruses have developed highlyeffective stratagems that undermine and block a wide variety ofhost inflammatory and immune responses. Some of the most potent of these immune modifying strategies utilize serpins that have also been developed over millions ofyears. including the hijacking by some viruses for defense against host immune attacks . Serpins represent up to 2-10 percent ofcirculating plasma proteins. regulating actions as wide ranging as thrombosis. inflammation. blood pressure control and even hormone transport. Targeting serpin-regulated immune or inflammatory pathways makes evolutionary sense for viral defense and many of these virus-derived inh ibitory proteins have proven to be highly effective.working at very low concentrations-even down to the femptomolar to picomolar range. We are studying these viral anti-inflammatory proteins as a new class ofimmunomodulatory therapeutic agents derived from their native viral source. One such viral serpin, Serp-I is now in clinical trial (conducted by VIRON Therapeutics, Inc.) for acute unstable coronary syndromes (unstable angina and small heart attacks), representing a 'first in class' therapeutic study. Several other viral serpins are also currently under investigation as anti-inflammatory or anti-immune therapeutics. This chapter describes these original studies and the ongoing analysis ofviral serpins as a new class ofvirus-derived immunotherapeutic.

UR - http://www.scopus.com/inward/record.url?scp=75649117820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75649117820&partnerID=8YFLogxK

U2 - 10.1007/978-1-4419-1601-3_11

DO - 10.1007/978-1-4419-1601-3_11

M3 - Chapter

C2 - 20054981

AN - SCOPUS:75649117820

SN - 9781441916006

T3 - Advances in Experimental Medicine and Biology

SP - 132

EP - 156

BT - Pathogen-Derived Immunomodulatory Molecules

A2 - Fallon, Padraic

ER -